Positron emission tomography findings in clinical mimics of lymphoma

Annals of the New York Academy of Sciences

Volumn 1228, Issue 1, 2011, Pages 19-28

  Aragon Ching, Jeanny B ^a   Akin, Esma A ^a  

^a GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Inflammation; Lymphoma; Positron emission tomography (PET)

Indexed keywords

ALLOPURINOL; ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; ATENOLOL; CAPTOPRIL; CARBAMAZEPINE; FLUORODEOXYGLUCOSE F 18; GLUCOSE; GLUCOSE TRANSPORTER 1; GOLD; HYDRALAZINE; PENICILLIN G; PHENYTOIN; PRIMIDONE; PYRIMETHAMINE; QUINIDINE; RADIOPHARMACEUTICAL AGENT; SULFONAMIDE; SULINDAC;

ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; ANTIBIOTIC THERAPY; ARTICLE; ATYPICAL MYCOBACTERIOSIS; AUTOIMMUNE DISEASE; B LYMPHOCYTE; BASAL GANGLION; BRAIN CORTEX; CANCER CHEMOTHERAPY; CD4+ T LYMPHOCYTE; CEREBELLUM; CONNECTIVE TISSUE DISEASE; DIAGNOSTIC ACCURACY; DRUG HYPERSENSITIVITY; DRUG UPTAKE; GRANULOMATOSIS; HEART MUSCLE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTIOUS MONONUCLEOSIS; KIKUCHI DISEASE; LYMPHADENOPATHY; LYMPHOMA; MYCOBACTERIUM TUBERCULOSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PHOSPHORYLATION; POSITRON EMISSION TOMOGRAPHY; PREMEDICATION; RETICULOENDOTHELIAL SYSTEM; RHEUMATOID ARTHRITIS; ROSAI DORFMAN DISEASE; SARCOIDOSIS; SENSITIVITY AND SPECIFICITY; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; THALAMUS; TOXOPLASMOSIS; TUBERCULOSIS; UROGENITAL SYSTEM; VIRUS LOAD; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 79959793737     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2011.06019.x     Document Type: Article

References (73)

1. Metser, U. & E. Even-Sapir 2007. Increased (18)F-fluorodeoxyglucose uptake in benign, nonphysiologic lesions found on whole-body positron emission tomography/computed tomography (PET/CT): accumulated data from four years of experience with PET/CT. Semin. Nucl. Med. 37: 206-222.
2. Metser, U. et al 2007. Benign nonphysiologic lesions with increased 18F-FDG uptake on PET/CT: characterization and incidence. AJR Am. J. Roentgenol. 189: 1203-1210.
3. Mittra, E. & A. Quon 2009. Positron emission tomography/computed tomography: the current technology and applications. Radiol. Clin. North Am. 47: 147-160.
4. Jaffe, E.S. 2009. The 2008 WHO classification of lymphomas: implications for clinical practice and translational research. Hematology Am. Soc. Hematol. Educ. Program 1: 523-531.
5. Zinzani, P.L. et al 2011. Midtreatment (18)F-fluorodeoxyglucose positron-emission tomography in aggressive non-Hodgkin lymphoma. Cancer 117:(5) 1010-1018.
6. Seam, P., M.E. Juweid & B.D. Cheson 2007. The role of FDG-PET scans in patients with lymphoma. Blood 110: 3507-3516.
7. Kelloff, G.J. et al 2007. FDG-PET lymphoma demonstration project invitational workshop. Acad. Radiol. 14: 330-339. doi.
8. Terezakis, S.A. et al 2010. [(18)F]FDG-positron emission tomography coregistration with computed tomography scans for radiation treatment planning of lymphoma and hematologic malignancies. Int. J. Radiat. Oncol. Biol. Phys. doi.
9. Tatsumi, M. et al 2005. Direct comparison of FDG PET and CT findings in patients with lymphoma: initial experience. Radiology 237: 1038-1045.
10. Kostakoglu, L. et al 2004. PET-CT fusion imaging in differentiating physiologic from pathologic FDG uptake. Radiographics 24: 1411-1431.
11. Brown, J.R. & A.T. Skarin 2004. Clinical mimics of lymphoma. Oncologist 9: 406-416.
12. Abouzied, M.M., E.S. Crawford & H.A. Nabi 2005. 18F-FDG imaging: pitfalls and artifacts. J. Nucl. Med. Technol. 33: 145-155; quiz 162-163.
13. Buck, A.K. & S.N. Reske 2004. Cellular origin and molecular mechanisms of 18F-FDG uptake: is there a contribution of the endothelium? J. Nucl. Med. 45: 461-463.
14. Fu, Y. et al 2004. Facilitative glucose transporter gene expression in human lymphocytes, monocytes, and macrophages: a role for GLUT isoforms 1, 3, and 5 in the immune response and foam cell formation. Blood Cells Mol. Dis. 32: 182-190.
15. Ishimori, T. et al 2002. Increased (18)F-FDG uptake in a model of inflammation: concanavalin A-mediated lymphocyte activation. J. Nucl. Med. 43: 658-663.
16. Zhao, S. et al 2002. Fluorodeoxyglucose uptake and glucose transporter expression in experimental inflammatory lesions and malignant tumours: effects of insulin and glucose loading. Nucl. Med. Commun. 23: 545-550.
17. Hubner, K.F. et al 1996. Differentiating benign from malignant lung lesions using "quantitative" parameters of FDG PET images. Clin. Nucl. Med. 21: 941-949.
18. Ho, C.L. 2004. Clinical PET imaging: an Asian perspective. Ann. Acad. Med. Singapore 33: 155-165.
19. Dewan, N.A. et al 1997. Likelihood of malignancy in a solitary pulmonary nodule: comparison of Bayesian analysis and results of FDG-PET scan. Chest 112: 416-422.
20. Zhuang, H. et al 2001. Dual time point 18F-FDG PET imaging for differentiating malignant from inflammatory processes. J. Nucl. Med. 42: 1412-1417.
21. Lan, X.L. et al 2008. The value of dual time point (18)F-FDG PET imaging for the differentiation between malignant and benign lesions. Clin. Radiol. 63: 756-764.
22. Harkirat, S. et al 2008. Pictorial essay: PET/CT in tuberculosis. Indian J. Radiol. Imaging 18: 141-147.
23. Liu, R.S., H.R. Shei & C.F. Feng 2002. Combined 18F-FDG and 11C-acetate PET imaging in diagnosis of pulmonary tuberculosis. J. Nucl. Med. 43: 127.
24. Basu, S. et al 2009. Positron emission tomography as a diagnostic tool in infection: present role and future possibilities. Semin. Nucl. Med. 39: 36-51.
25. Camacho, D.L., J.K. Smith & M. Castillo 2003. Differentiation of toxoplasmosis and lymphoma in AIDS patients by using apparent diffusion coefficients. AJNR Am. J. Neuroradiol. 24: 633-637.
26. Heald, A. E. et al 1996. Differentiation of central nervous system lesions in AIDS patients using positron emission tomography (PET). Int. J. STD AIDS 7: 337-346.
27. Hoffman, J.M. et al 1993. FDG-PET in differentiating lymphoma from nonmalignant central nervous system lesions in patients with AIDS. J. Nucl. Med. 34: 567-575.
28. O'Doherty, M.J. et al 1997. PET scanning and the human immunodeficiency virus-positive patient. J. Nucl. Med. 38: 1575-1583.
29. Pierce, M.A. et al 1995. Evaluating contrast-enhancing brain lesions in patients with AIDS by using positron emission tomography. Ann. Intern. Med. 123: 594-598.
30. Scharko, A.M. et al 2003. Whole-body positron emission tomography in patients with HIV-1 infection. Lancet 362: 959-961.
31. Liu, Y. 2009. Clinical significance of diffusely increased splenic uptake on FDG-PET. Nucl. Med. Commun. 30: 763-769.
32. Goshen, E. et al 2008. PET/CT in the evaluation of lymphoma in patients with HIV-1 with suppressed viral loads. Clin. Nucl. Med. 33: 610-614.
33. Rajeswaran, G. et al 2006. The radiology of IRIS (immune reconstitution inflammatory syndrome) in patients with mycobacterial tuberculosis and HIV co-infection: appearances in 11 patients. Clin. Radiol. 61: 833-843.
34. Kejariwal, D. et al 2001. Pyrexia of unknown origin: a prospective study of 100 cases. J. Postgrad. Med. 47: 104-107.
35. Demura, Y. et al 2009. Usefulness of 18F-fluorodeoxyglucose positron emission tomography for diagnosing disease activity and monitoring therapeutic response in patients with pulmonary mycobacteriosis. Eur. J. Nucl. Med. Mol. Imaging. 36: 632-639.
36. Davis, S. L. et al 2009. Noninvasive pulmonary [18F]-2-fluoro-deoxy-D-glucose positron emission tomography correlates with bactericidal activity of tuberculosis drug treatment. Antimicrob. Agents Chemother. 53: 4879-4884.
37. Bakheet, S. M. et al 1998. F-18-FDG uptake in tuberculosis. Clin. Nucl. Med. 23: 739-742.
38. Yang, C.M. et al 2003. Intense uptake of [F-18]-fluoro-2 deoxy-D-glucose in active pulmonary tuberculosis. Ann. Nucl. Med. 17: 407-410.
39. Tomas, M.B. et al 2000. 22. FDG uptake in infectious mononucleosis. Clin. Positron Imaging 3: 176.
40. Banzo, J. et al 2010. [(18)F-FDG PET-CT in cytomegalovirus-induced mononucleosis.]. Rev. Esp. Med. Nucl. 29: 304-307.
41. Lustberg, M.B., O. Aras & B.R. Meisenberg 2008. FDG PET/CT findings in acute adult mononucleosis mimicking malignant lymphoma. Eur. J. Haematol. 81: 154-156.
42. Matthies, A. et al 2002. Dual time point 18F-FDG PET for the evaluation of pulmonary nodules. J. Nucl. Med. 43: 871-875.
43. Dobert, N. et al 2004. Limitations of dual time point FDG-PET imaging in the evaluation of focal abdominal lesions. Nuklearmedizin 43: 143-149.
44. Lewis, P.J. & A. Salama 1994. Uptake of fluorine-18-fluorodeoxyglucose in sarcoidosis. J. Nucl. Med. 35: 1647-1649.
45. Alavi, A., C.A. Buchpiguel & A. Loessner 1994. Is there a role for FDG PET imaging in the management of patients with sarcoidosis? J. Nucl. Med. 35: 1650-1652.
46. Brudin, L.H. et al 1994. Fluorine-18 deoxyglucose uptake in sarcoidosis measured with positron emission tomography. Eur. J. Nucl. Med. 21: 297-305.
47. Yamada, Y. et al 1998. Fluorine-18-fluorodeoxyglucose and carbon-11-methionine evaluation of lymphadenopathy in sarcoidosis. J. Nucl. Med. 39: 1160-1166.
48. Costabel, U. et al 2010. Diagnostic modalities in sarcoidosis: BAL, EBUS, and PET. Semin. Respir. Crit. Care Med. 31: 404-408.
49. Taaleb, K., K.P. Kaiser & H. Wieler 2000. Elevated uptake of F-18 FDG in PET scans in nonmalignant disease. Clin. Nucl. Med. 25: 939-940.
50. Yasuda, S.S. et al 1996. High fluorine-18-deoxyglucose uptake in sarcoidosis. Clin. Nucl. Med. 21: 983-984 Abstract.
51. de Hemricourt, E. et al 2003. Sarcoidosis and sarcoid-like reaction following Hodgkin's disease. Report of two cases. Mol. Imaging Biol. 5: 15-19.
52. Hunt, B.M. et al 2009. Sarcoidosis as a benign cause of lymphadenopathy in cancer patients. Am. J. Surg. 197: 629-632; discussion 632.
53. Chowdhury, F.U. et al 2009. Sarcoid-like reaction to malignancy on whole-body integrated (18)F-FDG PET/CT: prevalence and disease pattern. Clin. Radiol. 64: 675-681.
54. Gotthardt, M. et al 2010. Imaging of inflammation by PET, conventional scintigraphy, and other imaging techniques. J. Nucl. Med. 51: 1937-1949.
55. Segal, G.H., J.D. Clough & R.R. Tubbs 1993. Autoimmune and iatrogenic causes of lymphadenopathy. Semin. Oncol. 20: 611-626.
56. Kojima, M. et al 1990. Reactive proliferative lesions in lymph nodes from rheumatoid arthritis patients. A clinicopathological and immunohistological study. Acta. Pathol. Jpn. 40: 249-254.
57. Nowak, M. et al 2004. A pilot study of the use of 2-[18F]-fluoro-2-deoxy-D-glucose-positron emission tomography to assess the distribution of activated lymphocytes in patients with systemic lupus erythematosus. Arthritis Rheum. 50: 1233-1238.
58. Serizawa, I. et al 2007. Lymphadenopathy due to amyloidosis secondary to Sjogren syndrome and systemic lupus erythematosus detected by F-18 FDG PET. Clin. Nucl. Med. 32: 881-882.
59. Fey, G.L. et al 2004. 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography uptake in systemic lupus erythematosus-associated adenopathy. Mol. Imaging Biol. 6: 7-11.
60. Pangalis, G.A. et al 1993. Clinical approach to lymphadenopathy. Semin. Oncol. 20: 570-582.
61. Harris, N.L. & D.J. Widder 1983. Phenytoin and generalized lymphadenopathy. Arch. Pathol. Lab Med. 107: 663-664.
62. Norris, A.H. et al 1996. Kikuchi-Fujimoto disease: a benign cause of fever and lymphadenopathy. Am. J. Med. 101: 401-405.
63. Ito, K., M. Morooka & K. Kubota 2010. Kikuchi disease: 18F-FDG positron emission tomography/computed tomography of lymph node uptake. Jpn. J. Radiol. 28: 15-19.
64. Rosai, J. & R.F. Dorfman 1972. Sinus histiocytosis with massive lymphadenopathy: a pseudolymphomatous benign disorder. Analysis of 34 cases. Cancer 30: 1174-1188.
65. Menzel, C. et al 2003. PET imaging of Rosai-Dorfman disease: correlation with histopathology and ex-vivo beta-imaging. Arch. Dermatol. Res. 295: 280-283.
66. Yu, J.Q. et al 2004. Demonstration of increased FDG activity in Rosai-Dorfman disease on positron emission tomography. Clin. Nucl. Med. 29: 209-210.
67. Hock, A.T. et al 2010. Rosai-Dorfman disease: FDG PET/CT findings in a patient presenting with pyrexia and cervical adenopathy. Clin. Nucl. Med. 35: 576-578.
68. Foucar, E., J. Rosai & R.F. Dorfman 1984. Sinus histiocytosis with massive lymphadenopathy. An analysis of 14 deaths occurring in a patient registry. Cancer 54: 1834-1840.
69. Castleman, B. & V.W. Towne 1954. Case records of the Massachusetts General Hospital; weekly clinicopathological exercises; founded by Richard C. Cabot. N. Engl. J. Med. 251: 396-400.
70. Castleman, B., L. Iverson & V.P. Menendez 1956. Localized mediastinal lymphnode hyperplasia resembling thymoma. Cancer 9: 822-830.
71. Onik, G. & P.C. Goodman 1983. CT of Castleman disease. AJR Am. J. Roentgenol. 140: 691-692.
72. Murphy, S.P., M.A. Nathan & M.W. Karwal 1997. FDG-PET appearance of pelvic Castleman's disease. J. Nucl. Med. 38: 1211-1212.
73. Madan, R. et al 2010. The spectrum of Castleman's disease: mimics, radiologic pathologic correlation and role of imaging in patient management. Eur. J. Radiol. doi.